Nippon India Pharma Fund-Growth
The fund is rated 0 stars. Balance between returns and downside risk provided limited support. Investment selection within each asset type and investment selection within each industry were the main limitations and did not provide enough support for a higher rating. Higher annual fee of 1.84% and above-average fund size of Rs 9,479.08 crore were minor drawbacks.
This fund has a bad track record with Asset Selection/Timing, a bad track record with Stock Selection/Timing. It is important to note, however, that this fund has a 9479.076 AUM and a 1.84 expense ratio. Considering all these factors, we have rated this fund as 0.0 star.
અમારો સ્કોર લાંબા ગાળાની કામગીરી, જોખમ અને સાતત્યને વજન આપે છે — ફક્ત ભૂતકાળના વળતરને નહીં.
રિટર્ન
8 Oct 2026 મુજબ
જોખમ ગુણોત્તર
30 Sep 2026 મુજબ
પોર્ટફોલિયો
31 Aug 2026 મુજબ
માર્કેટ-કેપ વિભાજન
સેક્ટર ફાળવણી
હોલ્ડિંગ્સ (37)
| હોલ્ડિંગ | ફંડનો % | મૂલ્ય | શેર |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 12.37% | ₹1,172.29 Cr | 59,06,349 |
| Divi's Laboratories Ltd. | 7.00% | ₹663.4 Cr | 7,00,754 |
| Lupin Ltd. | 6.43% | ₹609.25 Cr | 27,83,991 |
| Cipla Ltd. | 6.09% | ₹577.08 Cr | 40,95,054 |
| Apollo Hospitals Enterprise Ltd. | 5.15% | ₹488.35 Cr | 5,48,795 |
| Dr. Reddy's Laboratories Ltd. | 4.93% | ₹467.5 Cr | 40,49,746 |
| Mankind Pharma Ltd. | 4.09% | ₹387.93 Cr | 16,03,562 |
| Sai Life Sciences Ltd. | 3.94% | ₹373.06 Cr | 25,55,745 |
| Ajanta Pharma Ltd. | 3.47% | ₹329.18 Cr | 9,13,918 |
| Glaxosmithkline Pharmaceuticals Ltd. | 3.31% | ₹314 Cr | 10,29,460 |
ફંડ વિગતો
Long term capital growth. Investment in equity and equity related Securities of pharma & other associated companies.
The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies.
Exit load of 1% if redeemed within 1 month.